CordenPharma Plankstadt, located near Heidelberg, Germany, are experts in the development and manufacturing of solid dosage forms, specialising in the safe handling of highly potent application programme interfaces (APIs) and drug products, with a full range of services from pharmaceutical development for phase I-III to commercial-scale manufacturing, packaging and pharma-logistics (CEE-hub).
The expansion of the production capabilities at CordenPharma Plankstadt are the result of a new, long-term custom manufacturing agreement for an animal health application, which the company recently signed.
Frank Hähner, Managing Director of CordenPharma Plankstadt, said: “This is an extremely important and significant investment for CordenPharma Plankstadt. This new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of veterinary drug products. This is a unique opportunity in the industry.”
Work will commence in the second quarter of 2017, with a targeted mechanical completion by the second quarter of 2018 and commercial supply for the global launch campaign planned to start in the second half of 2018.
CordenPharma Plankstadt has supported the customer over the last year and a half, from initial technology transfer and development activities to the timely manufacturing of registration batches.
Michael Quirmbach, Vice President of Global Marketing & Sales at CordenPharma International, said: “CordenPharma’s goal is to be the leading CDMO for the development and manufacturing of highly potent & oncology solid dosage forms, both now and in the future. This investment greatly contributes to that strategy, while further expanding and strengthening our capabilities and service offerings.”
The investment in CordenPharma Plankstadt is the latest of several announced investments made by CordenPharma during 2017, where further capacity expansion and capabilities were installed in CordenPharma Colorado and CordenPharma Plankstadt to meet growing customer demand.
